MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
9.60
+0.27
+2.89%
After Hours: 9.78 +0.18 +1.88% 17:11 03/06 EST
OPEN
10.03
PREV CLOSE
9.33
HIGH
10.03
LOW
9.11
VOLUME
11.53K
TURNOVER
--
52 WEEK HIGH
61.60
52 WEEK LOW
6.08
MARKET CAP
8.80M
P/E (TTM)
-0.0271
1D
5D
1M
3M
1Y
5Y
1D
TransCode Therapeutics Issues 1.14M Non-Voting Convertible Preferred Shares in Private Placement
Reuters · 5d ago
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal
TipRanks · 5d ago
TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics
Benzinga · 5d ago
Transcode Therapeutics enters exclusive license agreement with Unleash
TipRanks · 5d ago
TRANSCODE THERAPEUTICS INC - UNDER AGREEMENT, UNLEASH TO RECEIVE 1,136,364 SHARES OF TRANSCODE PREFERRED STOCK
Reuters · 5d ago
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates
Reuters · 5d ago
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal
Reuters · 5d ago
Weekly Report: what happened at RNAZ last week (0223-0227)?
Weekly Report · 6d ago
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.